Dean Capital Investments Management LLC Purchases 284,119 Shares of Evolent Health Inc (NYSE:EVH)

Dean Capital Investments Management LLC raised its position in Evolent Health Inc (NYSE:EVH) by 156.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 465,717 shares of the technology company’s stock after buying an additional 284,119 shares during the period. Evolent Health accounts for about 1.9% of Dean Capital Investments Management LLC’s investment portfolio, making the stock its 4th biggest position. Dean Capital Investments Management LLC owned 0.55% of Evolent Health worth $3,349,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in EVH. Aperio Group LLC acquired a new position in shares of Evolent Health during the second quarter worth approximately $40,000. ETRADE Capital Management LLC bought a new stake in shares of Evolent Health during the second quarter worth approximately $80,000. DekaBank Deutsche Girozentrale raised its stake in shares of Evolent Health by 94.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock worth $95,000 after buying an additional 5,856 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. raised its stake in shares of Evolent Health by 38.4% during the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock worth $123,000 after buying an additional 4,300 shares during the last quarter. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of Evolent Health during the second quarter worth approximately $125,000. Institutional investors own 98.41% of the company’s stock.

EVH stock traded up $0.11 during trading hours on Tuesday, reaching $9.38. The stock had a trading volume of 5,818 shares, compared to its average volume of 1,064,698. The stock has a market capitalization of $782.66 million, a PE ratio of -26.89 and a beta of 1.07. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a 50-day simple moving average of $7.69 and a 200 day simple moving average of $8.76. Evolent Health Inc has a fifty-two week low of $5.50 and a fifty-two week high of $26.96.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. The company had revenue of $220.14 million during the quarter, compared to analysts’ expectations of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. Evolent Health’s quarterly revenue was up 46.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.04) EPS. On average, sell-side analysts forecast that Evolent Health Inc will post -0.95 EPS for the current fiscal year.

In other Evolent Health news, Director Kenneth A. Samet purchased 7,200 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average cost of $7.04 per share, with a total value of $50,688.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Doug S. Aron purchased 10,550 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average cost of $8.20 per share, for a total transaction of $86,510.00. Company insiders own 4.50% of the company’s stock.

Several equities research analysts have commented on the stock. Piper Jaffray Companies upped their target price on shares of Evolent Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Cowen set a $18.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Oppenheimer set a $15.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research cut shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Cantor Fitzgerald set a $16.00 target price on shares of Evolent Health and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $15.75.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

See Also: Why is the price-sales ratio important?

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health Inc (NYSE:EVH).

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit